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 Inflammation pathology has been 
recognized in the various disease group, not 
only in infectious disease but also in non-
infectious disease as seen in autoimmune 
rheumatic disease, chronic kidney disease, 
cardiovascular disease, malignancy, etc. Study 
regarding bone metabolism in the 
inflammatory state has been another interest. 
The relations between osteoporosis and 
rheumatoid arthritis have been established, 
study by Hauser, et al, 2014 showing the 
incidence of osteoporosis in rheumatoid 
arthritis subjects was 29.9% compare to 17.4% 
in age and gender-matched control group.[1] 
Current understanding regarding inflammatory 
pathway leading to bone loss in rheumatoid 
arthritis involving not only the “well-known” 
RANK-RANKL pathway but also 
Wnt/Dkk1/sclerostin pathway that mediates by 
inflammatory cytokines such as IL-1, IL-6, IL-8 
and TNF-α, this also explain that treatment 
controlling inflammation and disease activity 
will also reduce bone loss.[2] Treatment of 
rheumatoid arthritis using an anti-IL6 
monoclonal antibody (tocilizumab) also shown 
to reduce bone loss in rheumatoid arthritis 
proven by BMD, P1NP, CTX-I, and Dkk-1 in 
several studies despite combination with MTX 
or as a monotherapy regimen.[3-5] In this issue, 
Megawanto, et al showing the result of their 
study that calcium serum in rheumatoid 
arthritis subjects does not correlate with BMD 
so does disease activity, measured with DAS28-
ESR.[6] While calcium serum consistently 
showing no correlation in other studies, 
interestingly this study does not found a 
correlation between disease activity and BMD, 
this study coining an issue that other factors 
besides disease activity, which most of the 
items are clinical parameters, should be 
sought, such as immunologic parameters 
(cytokine, lymphocyte subsets, and 
osteoclasts) and other mediators (RANKL, OPG, 
sclerostin, etc.) 
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capacity. Altered bone and mineral metabolism 
also found in several chronic diseases, such as 
chronic kidney disease in form of chronic 
kidney disease-mineral bone disorder (CKD-
MBD). Jahidi, et al in this issue present their 
data regarding duration of hemodialysis and 
ADL score measured with Barthel index, 
showing that duration of hemodialysis does not 
associate with bone mineral parameters and 
ADL, but there is a tendency to increase 
phosphate levels in subjects that have 
performed hemodialysis more than a year, but 
not statistically significant (Jahidi, et al. 2020).[7] 
Interestingly mineral and bone disorder in 
chronic kidney disease showing that in 
regulating bone health several organs involved, 
the harmonious interrelation between organ 
and systems results in bone quality. Kidney has 
a role in maintaining phosphate homeostasis, 
vitamin D metabolism, and alteration of 
Wnt/Dkk1 pathway also exist in CKD. Another 
mechanism is the FGF23 pathway, a hormone 
that regulates phosphate excretions produced 
by osteoblast and osteocytes. FGF23 bind to 
klotho which number are reduced in subjects 
with CKD, resulting in an inability to excrete 
phosphate and causing hyperphosphatemia.[8] 
 Another interesting study in this issue 
by Nasution and Mustika showing the efficacy 
of telbivudine compare to tenofovir in the 
setting of HBV DNA levels at 12 months, 
proposing more efficacious results of 
telbivudine. There are controversial issues and 
study results regarding lower bone mineral 
density in subjects treated with tenofovir 
(especially Tenofovir Disoproxil Fumarate 
compare to Tenofovir Alafenamide) and some 
other antiviral drugs.[9] Winoto and 
Candradikusuma also reviewing shorter 
regimen for MDR tuberculosis, tuberculosis also 
increases the risk for osteoporosis and fracture, 
there is a lack of study comparing this risk 
between drug-sensitive and MDR 
tuberculosis.[10] 
 Compromise bone quality can be 
primarily caused by impaired bone metabolism 
as in osteoporosis, and altered bone 
metabolism as in chronic kidney disease, or as 
a result of chronic inflammation due to non-
infectious cause as in rheumatoid arthritis. 
Interestingly infection as a risk factor for 
compromised bone quality has been gaining 
attention, besides inflammation as the factors 
affecting bone metabolism, study on some 
medications also need to be elaborated.  
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